SCHEMBL20837283

SCHEMBL20837283

COc1ccc(C)c2ocnc12

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NQO2 P16083 5/20 0.41
MAPT P10636 2/20 0.40
ALDH1A1 P00352 4/20 0.38
LMNA P02545 3/20 0.35
KMT2A Q03164 1/20 0.35
POLB P06746 2/20 0.34
NPC1 O15118 1/20 0.34
G6PD P11413 1/20 0.34
PKM P14618 1/20 0.34
RAB9A P51151 1/20 0.34
CHRM4 P08173 1/20 0.34
HSD17B10 Q99714 3/20 0.33
HPGD P15428 3/20 0.33
ESR1 P03372 1/20 0.33
ESR2 Q92731 1/20 0.33
MAPK1 P28482 1/20 0.33
CYP19A1 P11511 1/20 0.33
PDGFRB P09619 1/20 0.33
PDGFRA P16234 1/20 0.33
SMN1; SMN2 Q16637 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20837272 0.80 NQO2 (0.40) NQO2MAPTALDH1A1LMNAKMT2A
SCHEMBL20837263 0.80 ALDH1A1 (0.43) NQO2MAPTALDH1A1KMT2APOLB
SCHEMBL6952678 0.80 NQO2 (0.49) NQO2MAPTALDH1A1LMNAKMT2A
SCHEMBL8404403 0.80 ELANE (0.33)
SCHEMBL25647658 0.76 TAAR1 (0.33) NQO2MAPTALDH1A1LMNAKMT2A
SCHEMBL20837066 0.76 MCL1 (0.38) NQO2ALDH1A1LMNAKMT2APOLB
SCHEMBL20837299 0.76 NQO2 (0.37) NQO2MAPTALDH1A1NPC1RAB9A
SCHEMBL20837396 0.76 ALDH1A1 (0.44) NQO2ALDH1A1MAOAKDM4E
SCHEMBL20837059 0.75 SMN1; SMN2 (0.42) NQO2ALDH1A1LMNAKMT2APOLB
SCHEMBL20837398 0.75 LMNA (0.49) NQO2MAPTALDH1A1LMNAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10738056-B2 Pyrazolopyrimidinone compounds and uses thereof ADURO BIOTECH INC. (US) 2020-08-11 US disclosed
US-20190119285-A1 PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF CHINOOK THERAPEUTICS, INC. 2019-04-25 US disclosed
WO-2019055750-A1 PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF Aduro Biotech, Inc. (US) 2019-03-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10738056-B2 Pyrazolopyrimidinone compounds and uses thereof NLRP3, NLRP1, P2RX7 NQO2 53/4885MAPT 214/4885ALDH1A1 1246/4885
US-20190119285-A1 PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF NLRP3, NLRP1, P2RX7 NQO2 53/4885MAPT 214/4885ALDH1A1 1246/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.